FDA Inspection 1118260 — National Cancer Institute, Cancer Therapy Evaluation Program
The FDA completed an inspection of National Cancer Institute, Cancer Therapy Evaluation Program on January 10, 2020 in Bethesda, MD. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- January 10, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Bethesda, MD (United States)
Additional Details
Sponsor, Contract Research Organization